← Back to Search

Glucagon Receptor Antagonist

LY3532226 for Type 1 Diabetes

Phase 1
Waitlist Available
Research Sponsored by Eli Lilly and Company
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Participants with type 1 diabetes mellitus (T1DM) for at least 2 years treated with insulin
Males or females not of childbearing potential
Timeline
Screening 3 weeks
Treatment Varies
Follow Up predose up to 120 mins postdose
Awards & highlights

Study Summary

This trial tests if a drug can help people with type 1 diabetes recover from low blood sugar caused by insulin. The trial will last 16 weeks.

Who is the study for?
This trial is for adults with Type 1 Diabetes Mellitus (T1DM) who have been managing their condition with insulin for at least two years. They should have a BMI between 18.5 to 40 kg/m² and not be able to bear children. Those recently in other studies, on certain diabetes medications, or using steroids can't participate.Check my eligibility
What is being tested?
The study tests LY3532226's effect on glucagon response during insulin-induced low blood sugar in T1DM patients compared to a placebo. It aims to see if the drug helps recover from low blood sugar better than no treatment over about four months.See study design
What are the potential side effects?
Potential side effects of LY3532226 are not detailed here but may include reactions similar to other diabetes treatments such as hypoglycemia, nausea, headache, or allergic responses.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have had type 1 diabetes for over 2 years and am on insulin.
Select...
I am not able to have children.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~predose up to 120 mins postdose
This trial's timeline: 3 weeks for screening, Varies for treatment, and predose up to 120 mins postdose for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Pharmacodynamics (PD): Area under the concentration versus time curve from time 60 to 120 minutes (AUC60-120min) of plasma glucagon during the insulin-induced hypoglycemia
Secondary outcome measures
Change from Baseline in Fasting and Post meal Glucose during Standardized Mixed-meal Tolerance Test (sMMTT)
Change from Baseline in Glucagon Concentration at Fasting and Post meal during sMMTT
The amount of exogenous glucose infused to maintain a plasma glucose level of >2.5 millimole per liter (mmol/L), after the insulin infusion is terminated.

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: LY3532226Experimental Treatment1 Intervention
Group II: PlaceboPlacebo Group1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
LY3532226
2023
Completed Phase 1
~170

Find a Location

Who is running the clinical trial?

Eli Lilly and CompanyLead Sponsor
2,615 Previous Clinical Trials
3,201,028 Total Patients Enrolled
Study DirectorEli Lilly and Company
1,344 Previous Clinical Trials
405,222 Total Patients Enrolled

Media Library

LY3532226 (Glucagon Receptor Antagonist) Clinical Trial Eligibility Overview. Trial Name: NCT05887999 — Phase 1
Type 1 Diabetes Research Study Groups: LY3532226, Placebo
Type 1 Diabetes Clinical Trial 2023: LY3532226 Highlights & Side Effects. Trial Name: NCT05887999 — Phase 1
LY3532226 (Glucagon Receptor Antagonist) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05887999 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

To what extent is LY3532226 detrimental to human health?

"LY3532226's safety rating is a 1, as the trial in question has only just entered Phase 1. This means there is still limited data available on its efficacy and safety."

Answered by AI

Would I qualify to partake in this research endeavor?

"This clinical trial is requesting applicants who are between 18 and 70 years old with type 1 diabetes. A maximum of 30 individuals will be selected for this investigation."

Answered by AI

Is this study currently enrolling participants?

"This trial is not currently enrolling, as indicated on clinicaltrials.gov. It was initially posted to the website on June 12th 2023 and last updated on May 25th 2023; nevertheless, there are still over a thousand other studies that require participants at this moment in time."

Answered by AI

Is this research initiative admitting participants of 35 years and above?

"Based on the specified qualifications for this clinical trial, potential participants must be between 18 and 70 years of age."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
A Study of LY3532226 in Participants With Type 1 Diabetes Mellitus
2023. "A Study of LY3532226 in Participants With Type 1 Diabetes Mellitus". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05887999.
~16 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top